Personalized Dosimetry As a Key for Optimizing Radioligand Therapy (RLT) with 177Lu- or 177Lu/90y-Dota-tate in Patients with Well-Differentiated Neuroendocrine Tumors - an Update on the Initial Results of the DUONEN Multicenter Study
Endocrine Abstracts（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined